Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age

Influenza Clinical Trial

Official title:

A Study to Evaluate the Safety and Immunogenicity of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children 6 Months to Less Than 9 Years of Age

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00976820
• Other study ID #: 113482
• Status: Completed
• Phase: Phase 2
• First received: September 11, 2009
• Last updated: November 10, 2017
• Start date: October 20, 2009
• Est. completion date: March 21, 2011

Study information

• Verified date: July 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to characterize the safety and immune response of the H1N1 (swine) flu vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age.

This Protocol Posting has been updated following the Protocol amendment 1 & 2, September and October 2009. The sections impacted are study design, objectives and analysis methods.

Description:

Collaborators: United States Department of Health and Human Services, Office of Biomedical Advanced Research and Development Authority

Recruitment information / eligibility

• Status: Completed
• Enrollment: 323
• Est. completion date: March 21, 2011
• Est. primary completion date: March 21, 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Months to 8 Years

Eligibility

Inclusion Criteria:

• Male or female children 6 months to less than 9 years of age at the time of the first vaccination.

• Written informed consent obtained from the subject's parent/ legally acceptable representative (LAR); written informed assent obtained from the subject if appropriate.

• Good general health as established by medical history and clinical examination before entering into the study.

• Safety laboratory test results within the parameters specified in the protocol.

• Parent/ LAR access to a consistent means of telephone contact, land line or mobile, but NOT a pay phone or other multiple-user device.

• Subjects who the investigator believes that their parent(s)/ LAR can and will comply with the requirements of the protocol.

• Female subjects of non-childbearing potential (pre-menarche) may be enrolled in the study.

Exclusion Criteria:

• Previous vaccination with an H1N1v-like virus vaccine or a medical history of physician-confirmed infection with an H1N1v-like virus.

• Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, even if stable, are deemed by the investigator to render the potential subject or parent(s)/ LAR(s) unable/unlikely to provide accurate safety reports.

• Presence of a temperature >= 38.0ºC (>=100.4ºF) by any route or method, or acute symptoms greater than "mild" severity on the scheduled date of first vaccination.

• Diagnosed with cancer, or treatment for cancer, within 3 years.

• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination

• Receipt of systemic glucocorticoids within 1 month prior to study enrollment, or any other cytotoxic or immunosuppressive drug within 6 months of study enrollment. Topical, intra-articular or inhaled glucocorticoids are allowed.

• Receipt of any immunoglobulins and/or any blood products within 3 months of study enrollment or planned administration of any of these products during the study period.

• Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin are eligible if no such doses are given in the 24 hours before a study vaccination. Persons receiving prophylactic antiplatelet medications, e.g., low-dose acetylsalicylic acid, and without a clinically-apparent bleeding tendency, are eligible.

• An acute evolving neurological disorder or history of Guillain-Barré syndrome within 6 weeks of receipt of seasonal influenza vaccine.

• Administration of any licensed vaccine within 4 weeks before the first dose of study vaccine, with the exception of seasonal influenza vaccine.

• Planned administration of any vaccine not foreseen by the study protocol between Day 0 and the Day 42 phlebotomy, including seasonal influenza vaccine. Routine childhood vaccinations are exempted if they cannot be delayed, but they must not be administered on the same day as the H1N1 vaccine candidate.

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.

• Any known or suspected allergy to any constituent of influenza vaccines a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine.

• Child in care.

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• GSK2340274A
Two intramuscular injections
• GSK2340273A
Two intramuscular injections

Locations

Country	Name	City	State
Canada	GSK Investigational Site	Brampton	Ontario
Canada	GSK Investigational Site	Coquitlam	British Columbia
Canada	GSK Investigational Site	Halifax	Nova Scotia
Canada	GSK Investigational Site	Hamilton	Ontario
Canada	GSK Investigational Site	Montreal	Quebec
Canada	GSK Investigational Site	Newmarket	Ontario
Canada	GSK Investigational Site	Quebec City	Quebec
Canada	GSK Investigational Site	Saint John's	Newfoundland and Labrador
Canada	GSK Investigational Site	Sherbrooke	Quebec
Canada	GSK Investigational Site	Sudbury	Ontario
Canada	GSK Investigational Site	Toronto	Ontario
Canada	GSK Investigational Site	Toronto	Ontario
Canada	GSK Investigational Site	Winnipeg	Manitoba
United States	GSK Investigational Site	Arkansas City	Kansas
United States	GSK Investigational Site	Austin	Texas
United States	GSK Investigational Site	Bardstown	Kentucky
United States	GSK Investigational Site	Cleveland	Ohio
United States	GSK Investigational Site	Conway	Arkansas
United States	GSK Investigational Site	Fort Worth	Texas
United States	GSK Investigational Site	Frisco	California
United States	GSK Investigational Site	Kingsport	Tennessee
United States	GSK Investigational Site	Little Rock	Arkansas
United States	GSK Investigational Site	Metairie	Louisiana
United States	GSK Investigational Site	Omaha	Nebraska
United States	GSK Investigational Site	Orem	Utah
United States	GSK Investigational Site	S. Jordan	Utah
United States	GSK Investigational Site	Sacramento	California
United States	GSK Investigational Site	Saint Paul	Minnesota
United States	GSK Investigational Site	San Angelo	Texas
United States	GSK Investigational Site	Wichita	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis	A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal hemagglutination inhibition (HI) titer lower than (<) 10 and a post-vaccination reciprocal HI titer higher than or equal to (=) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer = 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.	At Day 21
Primary	Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis	A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal HI titer < 10 and a post-vaccination reciprocal titer higher than or equal to (=) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer = 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.	At Day 21
Primary	Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis	A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal HI titer < 10 and a post-vaccination reciprocal titer higher than or equal to (=) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer = 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.	At Day 21
Primary	Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis	A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal HI titer < 10 and a post-vaccination reciprocal titer higher than or equal to (=) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer = 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.	At Day 42
Primary	Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis	A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal HI titer < 10 and a post-vaccination reciprocal titer higher than or equal to (=) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer = 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.	At Day 42
Primary	Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis	A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (=) 40 against the tested virus.	At Day 0
Primary	Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis	A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (=) 40 against the tested virus.	At Day 21
Primary	Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis	A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (=) 40 against the tested virus.	At Day 0
Primary	Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis	A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (=) 40 against the tested virus.	At Day 21
Primary	Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis	A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (=) 40 against the tested virus.	At Day 0
Primary	Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis	A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (=) 40 against the tested virus.	At Day 21
Primary	Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - First Analysis	A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (=) 40 against the tested virus.	At Day 0
Primary	Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - First Analysis	A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (=) 40 against the tested virus.	At Day 42
Primary	Number of Seroprotected Subjects Against Flu A/CAL/7/09 Strain - Second Analysis	A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (=) 40 against the tested virus.	At Day 0
Primary	Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain - Second Analysis	A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (=) 40 against the tested virus.	At Day 42
Primary	Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis	SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.	At Day 21
Primary	Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - First Analysis	SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.	At Day 21
Primary	Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Second Analysis	SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.	At Day 21
Primary	Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - First Analysis	SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.	At Day 42
Primary	Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain - Second Analysis	SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.	At Day 42
Secondary	Number of Seropositive Subjects for HI Antibodies - Preliminary Analysis	A seropositive subject was defined as a subject with antibody titers greater than or equal to (=) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.	At Day 0 (PRE) and at Day 21
Secondary	Number of Seropositive Subjects for HI Antibodies - First Analysis	A seropositive subject was defined as a subject with antibody titers greater than or equal to (=) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.	At Day 0 (PRE) and at Day 21
Secondary	Number of Seropositive Subjects for HI Antibodies - Second Analysis	A seropositive subject was defined as a subject with antibody titers greater than or equal to (=) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.	At Day 0 (PRE) and at Day 21
Secondary	Number of Seropositive Subjects for HI Antibodies - First Analysis	A seropositive subject was defined as a subject with antibody titers greater than or equal to (=) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.	At Day 0 (PRE) and at Day 42
Secondary	Number of Seropositive Subjects for HI Antibodies - Second Analysis	A seropositive subject was defined as a subject with antibody titers greater than or equal to (=) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.	At Day 0 (PRE) and at Day 42
Secondary	Number of Seropositive Subjects for HI Antibodies	A seropositive subject was defined as a subject with antibody titers greater than or equal to (=) 1:10. The vaccine strain assessed was Flu A/CAL/7/09.	At Day 0 (PRE) and at Day 182
Secondary	Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Preliminary Analysis	Titers are presented as geometric mean titers (GMTs) and measured in titers.	At Day 0 (PRE) and at Day 21
Secondary	Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis	Titers are presented as geometric mean titers (GMTs) and measured in titers.	At Day 0 (PRE) and at Day 21
Secondary	Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis	Titers are presented as geometric mean titers (GMTs) and measured in titers.	At Day 0 (PRE) and at Day 21
Secondary	Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - First Analysis	Titers are presented as geometric mean titers (GMTs) and measured in titers.	At Day 0 (PRE) and at Day 42
Secondary	Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain - Second Analysis	Titers are presented as geometric mean titers (GMTs) and measured in titers.	At Day 0 (PRE) and at Day 42
Secondary	Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the Flu A/CAL/7/09 Influenza Strain	Titers are presented as geometric mean titers (GMTs) and measured in titers.	At Day 0 (PRE) and at Day 182
Secondary	Number of Seroconverted Subjects Against Flu A/CAL/7/09 Influenza Strain	A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination reciprocal hemagglutination inhibition (HI) titer lower than (<) 10 and a post-vaccination reciprocal titer higher than or equal to (=) 40, or a pre-vaccination reciprocal hemagglutination inhibition (HI) titer = 10 and at least a 4-fold increase in post vaccination reciprocal titer against the vaccine virus.	At Day 182
Secondary	Number of Seroprotected Subjects Against Flu A/CAL/7/09 Influenza Strain	A seroprotected subject was defined as a vaccinated subject with reciprocal HI titers higher than or equal to (=) 40 against the tested virus.	At Day 0 (PRE) and at Day 182
Secondary	Seroconversion Factor (SCF) for HI Antibodies Against Flu A/CAL/7/09 Influenza Strain	SCF was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus.	At Day 182
Secondary	Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain	A seropositive subject was defined as a subject with antibody titers greater than or equal to (=) 1:8. The vaccine strain assessed was Flu A/Neth/602/09 H1N1.	At Day 0 (PRE) and at Day 21
Secondary	Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain	Titers are presented as geometric mean titers (GMTs) and measured in titers.	At Day 0 (PRE) and at Day 21
Secondary	Number of Seropositive Subjects for Neutralizing Antibodies Against Flu A/Neth/602/09 Influenza Strain	A seropositive subject was defined as a subject with antibody titers greater than or equal to (=) 1:8. The vaccine strain assessed was Flu A/Neth/602/09 H1N1.	At Day 0 (PRE) and at Day 42
Secondary	Titers for Neutralizing Antibodies Against the Flu A/Neth/602/09 Influenza Strain	Titers are presented as geometric mean titers (GMTs) and measured in titers.	At Day 0 (PRE) and at Day 42
Secondary	Number of Subjects With Vaccine Responses for Neutralizing Antibody Concentrations	Vaccine responses are defined as the incidence rate of vaccinated subjects with at least a 4-fold increase in post vaccination reciprocal titer relative to that prior to first vaccination. The vaccine strain assessed was Flu A/Neth/602/09 H1N1.	At Day 0 (PRE) and at Day 21
Secondary	Number of Subjects With Vaccine Responses for Neutralizing Antibody Concentrations	Vaccine response was defined as at least a 4-fold increase in post vaccination reciprocal titer relative to that prior to first vaccination. The vaccine strain assessed was Flu A/Neth/602/09.	At Day 0 (PRE) and at Day 42
Secondary	Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Preliminary Analysis	Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.	During the 7-day (Days 0-6) post-vaccination period
Secondary	Number of Subjects With Any and Grade 3 Solicited Local Symptoms - First Analysis	Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.	During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Secondary	Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Second Analysis	Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.	During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Secondary	Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis	Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [defined as axillary temperature equal to or above (=) 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 loss of appetite= not eating at all. Grade 3 fever = fever = 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.	During the 7-day (Days 0-6) post-vaccination period
Secondary	Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - Preliminary Analysis	Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches, shivering, sweating, temperature [defined as axillary temperature equal to or above (=) 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever = 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.	During the 7-day (Days 0-6) post-vaccination period
Secondary	Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - First Analysis	Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [defined as axillary temperature equal to or above (=) 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever = 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.	During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Secondary	Number of Subjects Aged Between 6 to Less Than 9 Years With Any, Grade 3 and Related Solicited General Symptoms - First Analysis	Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches, and shivering, sweating, temperature [defined as axillary temperature equal to or above (=) 38 degrees Celsius (° C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever = 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.	During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Secondary	Number of Subjects Less Than 6 Years Old With Any, Grade 3 and Related Solicited General Symptoms - Second Analysis	Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and temperature [defined as axillary temperature equal to or above (=) 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever = 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.	During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Secondary	Number of Subjects Aged Between 6 and 9 Years With Any, Grade 3 and Related Solicited General Symptoms- Second Analysis	Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, joint pain at other location, muscle aches, shivering, sweating and temperature [defined as axillary temperature equal to or above (=) 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever = 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.	During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Secondary	Number of Subjects With Haematological Laboratory Abnormalities - Preliminary Analysis	Among haematological parameters assessed were basophils [BAS], eosinophils [EOS], hematocrit [HCT], hemoglobin level [HGB], lymphocytes [LYM], monocytes [MON], neutrophils [NEU], platelet count [PLC], red blood cells [RBC] and white blood cells [WBC]. Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.	At Day 0 (PRE), at Day 7 and at Day 21
Secondary	Number of Subjects With Biochemical Laboratory Abnormalities - Preliminary Analysis	Biochemical parameters assessed for lab abnormalities were alanine aminotransferase [ALT], aspartate aminotransferase [AST], bilirubin [BLR], bilirubin conjugated/direct [BCD], creatinine [CRE] and blood urea nitrogen [BUN]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.	At Day 0 (PRE), at Day 7 and at Day 21
Secondary	Number of Subjects With Haematological Laboratory Abnormalities - First Analysis	Among haematological parameters assessed were basophils [BAS], eosinophils [EOS], hematocrit [HCT], hemoglobin level [HGB], lymphocytes [LYM], monocytes [MON], neutrophils [NEU], platelet count [PLC], red blood cells [RBC] and white blood cells [WBC]. Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.	At Day 0 (PRE), at Day 7, at Day 21 and at Day 42
Secondary	Number of Subjects With Biochemical Laboratory Abnormalities - First Analysis	Biochemical parameters assessed for lab abnormalities were alanine aminotransferase [ALT], aspartate aminotransferase [AST], bilirubin [BLR], bilirubin conjugated/direct [BCD], creatinine [CRE] and blood urea nitrogen [BUN]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.	At Day 0 (PRE), at Day 7, at Day 21 and at Day 42
Secondary	Number of Subjects With Haematological Laboratory Abnormalities - Second Analysis	Among haematological parameters assessed were basophils [BAS], eosinophils [EOS], hematocrit [HCT], hemoglobin level [HGB], lymphocytes [LYM], monocytes [MON], neutrophils [NEU], platelet count [PLC], red blood cells [RBC] and white blood cells [WBC], Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.	At Day 0 (PRE), at Day 7 and at Day 21
Secondary	Number of Subjects With Biochemical Laboratory Abnormalities - Second Analysis	Biochemical parameters assessed for lab abnormalities were alanine aminotransferase [ALT], aspartate aminotransferase [AST], bilirubin [BLR], bilirubin conjugated/direct [BCD], creatinine [CRE] and blood urea nitrogen [BUN]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.	At Day 0 (PRE), at Day 7, at Day 21 and at Day 42
Secondary	Number of Subjects With Haematological Laboratory Abnormalities	Among haematological parameters assessed were basophils [BAS], eosinophils [EOS], hematocrit [HCT], hemoglobin level [HGB], lymphocytes [LYM], monocytes [MON], neutrophils [NEU], platelet count [PLC], red blood cells [RBC] and white blood cells [WBC]. Haematological laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.	At Day 182
Secondary	Number of Subjects With Biochemical Laboratory Abnormalities	Biochemical parameters assessed for lab abnormalities were alanine aminotransferase [ALT], aspartate aminotransferase [AST], bilirubin [BLR], bilirubin conjugated/direct [BCD], creatinine [CRE] and blood urea nitrogen [BUN]. Biochemical laboratory values were unknown, below, within or above the laboratory reference range defined for the specified time point and laboratory parameter.	At Day 182
Secondary	Number of Subjects With Any Unsolicited Adverse Events (AEs) - Preliminary Analysis	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.	Within 21 days (Days 0-20) post vaccination
Secondary	Number of Subjects With Any Unsolicited Adverse Events (AEs) - First Analysis	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.	Within 42 days (Days 0-41) post vaccination
Secondary	Number of Subjects With Any Unsolicited Adverse Events (AEs) - Second Analysis	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.	Within 41 days (Days 0-40) post vaccination
Secondary	Number of Subjects With Any Unsolicited Adverse Events (AEs)	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.	Within 84 days (Days 0-83) post vaccination
Secondary	Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Preliminary Analysis	MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.	Within 21 days (Days 0-20) post vaccination
Secondary	Number of Subjects With Any Medically-attended Adverse Events (MAEs) - First Analysis	MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.	Within 41 days (Days 0-40) post vaccination
Secondary	Number of Subjects With Any Medically-attended Adverse Events (MAEs) - Second Analysis	MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.	Within 42 days (Days 0-41) post vaccination
Secondary	Number of Subjects With Any Medically-attended Adverse Events (MAEs)	MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.	Within 182 days (Days 0-181) post vaccination
Secondary	Number of Subjects With Any Medically-attended Adverse Events (MAEs)	MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.	Throughout the entire study period (Day 0 - Day 385)
Secondary	Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Preliminary Analysis	Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.	Within 21 days (Days 0-20) post vaccination
Secondary	Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - First Analysis	Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.	Within 42 days (Days 0-41) post vaccination
Secondary	Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs) - Second Analysis	Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.	Within 42 days (Days 0-41) post vaccination
Secondary	Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)	Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.	Within 182 days (Days 0-181) post vaccination
Secondary	Number of Subjects Reporting Any Potential Immune-mediated Diseases (pIMDs)	Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.	Throughout the entire study period (Day 0 - Day 385)
Secondary	Number of Subjects With Serious Adverse Events (SAEs) - Preliminary Analysis	Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	Within 21 days (Days 0-20) post vaccination
Secondary	Number of Subjects With Serious Adverse Events (SAEs) - First Analysis	Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	Within 42 days (Days 0-41) post vaccination
Secondary	Number of Subjects With Serious Adverse Events (SAEs) - Second Analysis	Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	Within 42 days (Day 0-41) post vaccination
Secondary	Number of Subjects With Serious Adverse Events (SAEs)	Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	Within 182 days (Days 0-181) post vaccination
Secondary	Number of Subjects With Serious Adverse Events (SAEs)	Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	Throughout the entire study period (Day 0 - Day 385)

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.